Kroger announces that its retail pharmacies have officially launched Zepbound® Kwikpen.

This initiative aims to provide self-paying patients with a more convenient way to access medication, while also alleviating their financial burden through cost optimization. This collaboration further strengthens Kroger's service capabilities in the pharmaceutical retail sector. Zepbound®, an innovative drug developed by Eli Lilly, features a Kwikpen formulation designed to enhance patient convenience. Analysts believe that expanding retail channels will help improve drug accessibility, especially for chronic disease patients who require long-term medication. Market observers point out that pharmaceutical retail companies can not only increase customer loyalty by introducing high-demand prescription drugs, but may also drive sales growth of related health consumer products. Kroger's strategic deployment reflects the increasingly important role of retail pharmacies within the healthcare ecosystem.